Replicel Is On Fire Lately — Data In Feb.

[That Guy]

That Guy,

You seem to talk sense. Are you optimistic about Follica? Like many, I had dismissed it as glorified needling and minoxidil. I haven’t tried needling, but from the results I’ve seen, it isn’t worth the hassle. For me, things like daily topical treatments or period, self-administered needling are only “worth it” if they provide consistent, noticeable results and thickening.

What makes you think Tsuji is “just around the corner”? If you had to make an educated guess, when do you think Tsuji will be available? I’m not disagreeing, by the way. I’m looking for reasons to be optimistic.

I am optimistic about Follica. The results of their studies; the trichograms and such are all encouraging and should be a good alternative to a transplant. Their protocol is also much more thorough than basic minoxidil + needling, not easy to just do on yourself, and reveals that they understand a lot more about the biological mechanisms of wounding to grow hair.

Tsuji's work is great. The hair that they've grown in the lab and on mice used human cells to do it; no reason it won't have the same effect on humans since it's already been shown to work using our cells. With Japan's laws and such, after they finish their trial in humans this year, they could release it and intend to.

The only thing about Tsuji is that it will be extraordinarily expensive and they have said probably limited to about 10,000 patients annually. It will be years, maybe decades, before it comes down in price and has wide availability.

 

[MeDK]

Replicels view on the recent RCH-01 study.

Also good to see that they have further developed the supple chain and preservation of the cells.

Cryopreservation

This study represents the first time this product, comprised of dermal sheath cup cells, was used clinically after being cryopreserved. In the phase I study, RepliCel shipped product under cool controlled-temperature conditions but not cryopreserved. Following the phase 1 trial, RepliCel conducted several studies at the University of British Columbia and its European-based contract manufacturer which demonstrated the stability and viability of thawed cells after control-rate freezing and cryopreserved storage.

The ability to store product long-term for future use and ship it over long-distances in highly-controlled formats provides distinct advantages to the products’ commercial margins and model. This technology and data was part of RepliCel’s technology transfer to Shiseido’s manufacturing facility and personnel. This study represents the first clinical confirmation of the product’s efficacy after cryopreservation.

 

[RolfLeeBuckler]

The question remains: when will RCH be commercially available in Japan though?

Shiseido planned for 2020 commercial launch of RCH-01 like I always said but it will be delayed due to corona. I hope that the Japanese government will accept medical tourism... after Corona it is extremely difficult

 

[MeDK]

The question remains: when will RCH be commercially available in Japan though?

Replicel have written they aim for a 2023 market launch for all of their products.

“This provides a clear signal to Japanese investors, clinicians, and strategic partners with whom we are in discussions, that we are delivering on our ‘First-in-Japan’ strategy which aims to have four products on the market in Japan by 2023.” - Replicel

And Replicel have only four products

RCH-01
RCS-01
RCT-01
RCI-02

 

[MeDK]

Okay interesting. Sucks we won't see it sooner but hey...

Btw isn't Shiseido going to do a new trial focused on efficiancy?

It sounds like they want to do multiple injections over time study maybe.

First was one injection one time, second was multiple injections one time. So maybe its multiple injections over time next time.

Who knows, but it seems to be the way they want to proceed at least.

 

[MeDK]

Good they're still going further with it.

But sucks we won't see this commercialy available anytime soon...damn

at least we have a "dot" in the horizon that tells us that in 2023 they have set a goal for first in japan with their products. Maybe its pushed a bit because of the new world situation. But we got some direction and a timeline.

 

[RolfLeeBuckler]

Before corona SHISEIDO aimed commercialization of hair regeneration in 2020 which I always said and got dislikes for it.

 

[Fgsfds]

Before corona SHISEIDO aimed commercialization of hair regeneration in 2020 which I always said and got dislikes for it.View attachment 139980View attachment 139981

Nobody cares you stupid nig. Why are you bringing up old news from 2018? Shiseido said they're going to conduct another trial with the hopes of commercializing RCH-01, and that's that.

 

[Ollie]

Is it even worth talking about anymore given how cosmetically poor the recent results are. I'd be more excited over Bayer's PRL antigen injections.

 

[Throwaway94]

Replicel have written they aim for a 2023 market launch for all of their products.

“This provides a clear signal to Japanese investors, clinicians, and strategic partners with whom we are in discussions, that we are delivering on our ‘First-in-Japan’ strategy which aims to have four products on the market in Japan by 2023.” - Replicel

And Replicel have only four products

RCH-01
RCS-01
RCT-01
RCI-02

The issue there is that Replicel have absolutely no say in the commercialisation of RCH-01 in Japan so their aims don't mean anything to us

 

[NilesCrane]

God damn it...always three years away...for a subpar treatment...f*** balding!!! Sorry just one of those days lol

 

[Joxy]

This trial was done by very credible universities/scientists. I hope Shiseido/Replicel learned a lot from this trial what they should do in future and how to improve this treatment.

 

[Joxy]

They learned what not to do. lol Problem is there's still an almost infinite number of ways in which they can fail.

Clinical results are based only on one injection.

 

[MeDK]

They learned what not to do. lol Problem is there's still an almost infinite number of ways in which they can fail.

They are understanding their procedure better and better.

So its better they make the mistakes now and learn from them, instead of trying to rush it. That is what the clinical trails are for. It is to learn and understand, and you only do that by making mistakes, and they have shown to learn from it.

But I think they are beyond the point of failing. What should they be failing with?

 

[MeDK]

The issue there is that Replicel have absolutely no say in the commercialisation of RCH-01 in Japan so their aims don't mean anything to us

Why don't they have anything to say?

Its Replicel that helps Shiseido to design, validate, and prepare Shiseidos SPEC facility. Also Replicel and another company that have trained Shiseidos employees at the SPEC facility.

So why is it you think that Replicel have no saying in this?

 

[max310]

They are understanding their procedure better and better.

So its better they make the mistakes now and learn from them, instead of trying to rush it. That is what the clinical trails are for. It is to learn and understand, and you only do that by making mistakes, and they have shown to learn from it.

But I think they are beyond the point of failing. What should they be failing with?

Regardless!. Still .. this treatment will produce two thin ugly hairs that you will shave anyway. Or .. be the weird guy with garbage thin hair.

 

[Throwaway94]

Why don't they have anything to say?

Its Replicel that helps Shiseido to design, validate, and prepare Shiseidos SPEC facility. Also Replicel and another company that have trained Shiseidos employees at the SPEC facility.

So why is it you think that Replicel have no saying in this?

They provided the technology and the training as part of the licensing agreement but only Shiseido is allowed to commercialise the treatment in Japan. Replicel effectively sold the rights to them. Replicel can commercialise anywhere else in the world but they'll have to go through a separate approval process, not Japan's accelerated one.

 

[MeDK]

They provided the technology and the training as part of the licensing agreement but only Shiseido is allowed to commercialise the treatment in Japan. Replicel effectively sold the rights to them. Replicel can commercialise anywhere else in the world but they'll have to go through a separate approval process, not Japan's accelerated one.

Shiseido is only allowed to release it with the approval of Replicel. Shiseido have nothing to sell if replicel doesn't allow them to use their technology.

 

[Throwaway94]

Shiseido is only allowed to release it with the approval of Replicel. Shiseido have nothing to sell if replicel doesn't allow them to use their technology.

You don't understand. Shiseido already have the technology as well as the exclusive right to commercialise in Japan, with or without "approval" from Replicel. Replicel have already sold it to them and Shiseido have already received the training and everything else they need. Replicel is out of the picture now besides the dispute regarding royalties if Shiseido do decide to commercialise.

 

[Throwaway94]

What made this treatment worthwhile was the belief that it would inoculate your existing hairs to be DHT resistant so you could just get a hair transplant. It obviously doesn't work that way, and never will. So what if they can give you the same regrowth as minoxidil five to ten years from now in Japan. Minoxidil can do that right now without leaving the house.

In fairness there's not enough information to determine whether or not the inoculation aspect is a thing or not. Either way I know there will be plenty of people interested both now and in the future. We're not all 10 years into the battle...